Recombinant Human Endostatin Market Size is valued at USD 133.3 Mn in 2023 and is predicted to reach USD 249.4 Mn by the year 2031 at a 8.3% CAGR during the forecast period for 2024-2031.
Recombinant human endostatin is a naturally occurring protein in the human body that prevents angiogenesis and has been bioengineered. Genetic engineering methods are used to generate the recombinant form for medical uses. The increasing number of cancer cases, advancements in biotechnology, large investments in research and development, and the demand for more targeted cancer treatments are all driving forces in the recombinant human endostatin market. The recombinant human endostatin business is booming due in large part to recent developments in biotechnology and genetic engineering that have allowed for more efficient and scalable production expansion in the coming years. Government programs to lower the cost of anticancer drugs and an uptick in R&D efforts to find new applications for recombinant human endostatin are further factors that could lead to growth in the market over the projection period.
However, the market expansion is hindered due to rigorous regulatory requirements, a lack of endostatin awareness and uptake among healthcare professionals, and restricted procurement alternatives, all of which contribute to an overall decrease in the availability of endostatin products, which slows down the recombinant human endostatin market growth. In addition, the recombinant human endostatin market was severely struck by the COVID-19 pandemic, which caused supply chain disruptions and clinical trial delays.
However, cutting-edge biotechnology remedies were brought to light by the pandemic, which could hasten the investment and research into cancer treatments in the future. Additionally, the rising need for endostatin medications in cancer therapy is expected to drive substantial expansion in the global recombinant human endostatin market during the forecast period.
The recombinant human endostatin market is segmented based on product type and application. Based on type, the market is segmented into purity 95% and others. The application segment is segmented into medical care, scientific research, and others.
The purity of 95% in the recombinant human endostatin market is expected to hold a major global market share in 2023 because therapeutic applications benefit from higher purity levels, which provide greater efficacy while being safe. Rising demand in medical and research contexts is being driven by the need for this high purity level, which is essential for clinical use and regulatory approvals. It meets demanding quality criteria and improves treatment outcomes, which is driving the segment growth.
The medical care industry is growing due to the growing need for new cancer treatments and the accompanying rise in cancer incidence rates. Recombinant human endostatin is one example of a targeted therapy that is seeing increased use due to developments in precision medicine and biotechnology. The medical care industry is poised for expansion because of a number of factors, including supportive regulatory climates and more financing for cancer research.
The North American recombinant human endostatin market is expected to report the largest market share in the near future. This is because the rapid acceptance of modern cancer therapies is facilitated by a combination of factors, including a highly developed healthcare infrastructure and substantial investments in research and development, which are in response to the increasing cancer incidence. Strong public and private sector funding for cancer research is also essential in this region. In addition, the Asia Pacific is estimated to grow rapidly in the global recombinant human endostatin market as a result of a number of factors, including an uptick in the number of recombinant human endostatin clinical trials, improvements in technology, increased spending on R&D by major firms, and a greater emphasis on personalized treatment.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 133.3 Mn |
|
Revenue Forecast In 2031 |
USD 249.4 Mn |
|
Growth Rate CAGR |
CAGR of 8.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Pfizer Inc., PeproTech, Inc., Onyx Pharmaceuticals, Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and Novartis AG. and Others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Recombinant Human Endostatin Market Snapshot
Chapter 4. Global Recombinant Human Endostatin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Purity 95%
5.2.2. Others
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Medical Care
6.2.2. Scientific Research
6.2.3. Others
Chapter 7. Recombinant Human Endostatin Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.1.2. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.1.3. North America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.2. Europe
7.2.1. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.2.2. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.2.3. Europe Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.3.2. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.3.3. Asia Pacific Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.4. Latin America
7.4.1. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.4.2. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.4.3. Latin America Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.5.2. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.5.3. Middle East & Africa Recombinant Human Endostatin Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Pfizer Inc.
8.2.2. Novus Biologicals
8.2.3. Biocon
8.2.4. Thermo Fisher Scientific
8.2.5. Yantai Medgenn Ltd.
8.2.6. FUJIFILM KYOWA KIRIN BIOLOGICS Co. Ltd.
8.2.7. PeproTech, Inc.
8.2.8. Onyx Pharmaceuticals, Inc.
8.2.9. Genexine, Inc.
8.2.10. Hetero.
8.2.11. Intas Pharmaceuticals Ltd.
8.2.12. Novartis AG.
8.2.13. Other Prominent Players
Recombinant Human Endostatin Market By Type-
Recombinant Human Endostatin Market By Application-
Recombinant Human Endostatin Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
